Violet Therapeutics secured a $4.8 million seed extension to advance its RABID-seq platform, which combines barcoded viral tracing with single-cell RNA sequencing to map interactions between brain cell types. The funding supports continued platform development and enables more precise interrogation of cellular communication relevant to therapeutic discovery. RABID-seq is positioned to reduce the measurement bottleneck in neuroscience-heavy drug development, where understanding connectivity and cell-to-cell signaling is often a prerequisite for choosing targets and designing interventions. The round signals continued investor appetite for tool-driven approaches that promise to improve target validation and mechanistic understanding ahead of later-stage clinical assets.